Sue Wang

SUE WANG is a trial lawyer who represents clients across the life sciences industry in high-stakes litigation involving intellectual property and complex commercial disputes. An experienced litigator, she has developed strategies and helped clients prevail in precedent-setting cases against generic, biosimilar, and innovator competitors.

A former federal district court clerk, Sue knows how to speak to judges and juries. She leverages her scientific training from an undergraduate degree in biological sciences and her legal experience to craft and deliver compelling narratives around complicated legal and technological issues. Outside the courtroom, Sue uses her litigator’s perspective to counsel clients on patent- and technology-related matters, including patent analysis for technology licenses and acquisitions, freedom-to-operate for pipeline products, and strategic planning for future litigation.

Sue maintains an active pro bono practice, representing individual and institutional clients on immigration-related issues such as asylum, temporary protected status, challenges to detention and enforcement policy, and Freedom of Information Act (FOIA) requests. Sue also serves as a court-appointed mediator for the Northern District of California’s Alternative Dispute Resolution program.

Sue clerked for The Honorable Judge Beth Labson Freeman in the Northern District of California from 2014–2015. She earned her J.D. from Stanford Law School, where she was a board member for the Stanford Technology Law Review. She received her B.A., with general honors, in biological sciences and political science from the University of Chicago.

In addition to her case accomplishments, Sue was named to Law360’s 2025 “Rising Stars” list for her work in intellectual property. She has also been recognized by Best Lawyers: Ones to Watch in America for Litigation – Intellectual Property in 2024 and 2025, and by Super Lawyers, Northern California as a “Rising Star” in Intellectual Property Litigation in 2021 and 2022.

Sue’s recent experience has involved technologies related to: small molecule pharmaceuticals and treatment methods; DNA sequencing; gene editing; RNA interference; antibody therapeutics; protein manufacturing processes; cancer immunotherapy; and T-cell therapies. Representative litigation matters include:

• Representing biopharmaceutical company in multi-district patent litigation under the BPCIA involving proposed biosimilars to company’s antibody biologic. Leading the development of core theories and strategy across cases in several jurisdictions including the District of New Jersey. One case settled favorably after a multi-day evidentiary hearing on a motion for preliminary injunction.
• Represented biopharmaceutical company in Hatch-Waxman litigation involving small-molecule psoriasis drug. As part of trial team in the District of New Jersey, helped secure ruling upholding validity of key patents. As part of appellate team, helped secure affirmance at the Federal Circuit. Awarded “Patent Impact Case of the Year” by LMG Life Sciences in 2023.
• Represented biopharmaceutical company in patent litigations involving biosimilars to the company’s blockbuster fusion protein biologic. As part of trial team, helped secure ruling upholding patent validity following a two-week bench trial in the District of New Jersey. As part of appellate team, helped secure affirmance at the Federal Circuit. Awarded “Impact Case of the Year” by LMG Life Sciences in 2020.
• Represented pharmaceutical company in multiple patent suits involving Factor VIII products. As part of trial team, helped secure a jury victory for the patent owner that resulted in one of the highest biotech verdicts in the District of Delaware. As part of appellate team, helped secure affirmance from the Federal Circuit on all issues. Cases settled favorably. Recognized in National Law Journal’s “Verdicts Hall of Fame” and awarded “Impact Case of the Year” by LMG Life Sciences in 2019.
• Representing multiple software developers in the Northern District of California in patent infringement lawsuits brought by non-practicing entity.
• Represented biopharmaceutical company in first-of-its-kind declaratory judgment patent litigation under the Biologics Price Competition and Innovation Act (BPCIA), successfully securing dismissal for lack of an Article III case or controversy.